# KSB TUGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ksb-tugen

- Industry: Healthcare
- Headquarters: Chungju, South Korea
- Website: www.ksbtugen.com
- Total disclosed funding: $3.6M
- Latest round: Series B (Oct 29, 2025)
- Investors on record: 4

## About

Based in Seoul, South Korea, and founded in 2020, KSBTUGEN Co., Ltd. operates as a pharmaceutical company that focuses on conducting research and development for the treatment of muscle-related diseases. In July 2021, KSB TUGEN Co., Ltd. raised KRW 200 million in venture funding from Infobank.

KSB TUGEN Co., Ltd. is a developer of therapeutics designed to provide treatment for intractable sarcopenia based on clinical multi-omics. The company's therapeutics provide senile sarcopenia treatment that helps to fight against diseases, enabling healthcare companies to provide patients with treatment solutions.

The company plans to use the July 2021 funding to expand its intellectual rights In the US, China, Germany, and will conduct research-led clinical trials as well.

## Funding rounds

- Series B, Oct 29, 2025, $3M — Hana Securities, Evergreen Investment Partners
- Seed, Jul 8, 2021, $0.6M — Infobank, PNP Investment

## Investors

- Infobank (https://capitalatlas.ai/funds/infobank) — Seed
- PNP Investment (https://capitalatlas.ai/funds/pnp-investment) — Seed
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B
- Evergreen Investment Partners (https://capitalatlas.ai/funds/evergreen-investment-partners) — Series B